JP2013505946A5 - - Google Patents

Download PDF

Info

Publication number
JP2013505946A5
JP2013505946A5 JP2012531043A JP2012531043A JP2013505946A5 JP 2013505946 A5 JP2013505946 A5 JP 2013505946A5 JP 2012531043 A JP2012531043 A JP 2012531043A JP 2012531043 A JP2012531043 A JP 2012531043A JP 2013505946 A5 JP2013505946 A5 JP 2013505946A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
moiety
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012531043A
Other languages
English (en)
Japanese (ja)
Other versions
JP5791611B2 (ja
JP2013505946A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/050079 external-priority patent/WO2011038162A1/en
Publication of JP2013505946A publication Critical patent/JP2013505946A/ja
Publication of JP2013505946A5 publication Critical patent/JP2013505946A5/ja
Application granted granted Critical
Publication of JP5791611B2 publication Critical patent/JP5791611B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012531043A 2009-09-23 2010-09-23 ピリド[3,4−b]インドールおよび使用方法 Expired - Fee Related JP5791611B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24514809P 2009-09-23 2009-09-23
US61/245,148 2009-09-23
PCT/US2010/050079 WO2011038162A1 (en) 2009-09-23 2010-09-23 Pyrido(3,4-b)indoles and methods of use

Publications (3)

Publication Number Publication Date
JP2013505946A JP2013505946A (ja) 2013-02-21
JP2013505946A5 true JP2013505946A5 (US07981874-20110719-C00313.png) 2013-11-07
JP5791611B2 JP5791611B2 (ja) 2015-10-07

Family

ID=43796210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012531043A Expired - Fee Related JP5791611B2 (ja) 2009-09-23 2010-09-23 ピリド[3,4−b]インドールおよび使用方法

Country Status (8)

Country Link
US (2) US20130137705A1 (US07981874-20110719-C00313.png)
EP (1) EP2480079A4 (US07981874-20110719-C00313.png)
JP (1) JP5791611B2 (US07981874-20110719-C00313.png)
CN (1) CN102711467A (US07981874-20110719-C00313.png)
AU (1) AU2010298167B2 (US07981874-20110719-C00313.png)
BR (1) BR112012006644A2 (US07981874-20110719-C00313.png)
CA (1) CA2775129A1 (US07981874-20110719-C00313.png)
WO (1) WO2011038162A1 (US07981874-20110719-C00313.png)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CA2719412A1 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
WO2009120720A1 (en) 2008-03-24 2009-10-01 Medivation Technologies,Inc. Bridged heterocyclic compounds and methods of use
TWI477503B (zh) 2008-10-31 2015-03-21 Medivation Technologies Inc 含有剛性部分之吡啶并〔4,3-b〕吲哚
EP2348847A4 (en) * 2008-10-31 2012-05-23 Medivation Technologies Inc AZEPINO [4, 5-B] INDOLE AND USE PROCESS
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
JP5711725B2 (ja) 2009-04-29 2015-05-07 メディベイション テクノロジーズ, インコーポレイテッド ピリド[4,3−b]インドールおよびその使用方法
AU2010282990B2 (en) 2009-04-29 2015-11-05 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
CA2775328A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[4,3-b]indoles and methods of use
EP2480080A4 (en) 2009-09-23 2014-01-08 Medivation Technologies Inc PYRIDO [3,4-B] INDOLES AND METHODS OF USE
CN102711466A (zh) 2009-09-23 2012-10-03 梅迪维新技术公司 桥连杂环化合物及其使用方法
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103460A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
EP2590647B1 (en) 2010-07-07 2017-11-08 Board of Regents of the University of Texas System Pro-neurogenic compounds
US9035056B2 (en) 2011-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2012112966A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112961A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating hypertension
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
CN104839184A (zh) * 2015-04-18 2015-08-19 广东中迅农科股份有限公司 含有氯吡嘧磺隆和氯氨吡啶酸以及烟嘧磺隆的农药组合物
EP3703716A4 (en) 2017-11-02 2021-12-01 California Institute of Technology EXPRESSION OF NEUROPEPTIDES
EP3704271A4 (en) * 2017-11-02 2021-09-08 California Institute of Technology NEUROKININ ANTAGONISTS AND RELATED USES

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642438A (en) * 1949-07-15 1953-06-16 Hoffmann La Roche Pyridindoles and method of manufacture
GB721171A (en) * 1951-04-30 1954-12-29 Bayer Ag Derivatives of ª‰- and ª†- carbolines
JPS3922979B1 (US07981874-20110719-C00313.png) * 1962-04-10 1964-10-15
JPS3920857B1 (US07981874-20110719-C00313.png) * 1962-05-17 1964-09-24
JPS412713B1 (US07981874-20110719-C00313.png) * 1963-08-30 1966-02-21
US4754038A (en) * 1987-02-26 1988-06-28 American Home Products Corporation Carboline histamine H1 antagonists
US5817756A (en) * 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
CA2171446C (en) * 1993-09-09 2004-11-23 Donald James Kyle Pseudo- and non-peptide bradykinin receptor antagonists
JPH09510216A (ja) * 1994-03-11 1997-10-14 イーライ・リリー・アンド・カンパニー 5−ht▲下2b▼受容体に関連する病態を治療するための方法
US5688807A (en) * 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
JPH11505217A (ja) * 1995-05-05 1999-05-18 ノボ ノルディスク アクティーゼルスカブ 新規複素環の化学
GB9604996D0 (en) * 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
AU1407399A (en) * 1997-11-14 1999-06-07 Eli Lilly And Company Treatment for alzheimer's disease
FR2771095B1 (fr) * 1997-11-14 1999-12-17 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1057814B1 (en) * 1997-12-25 2005-03-09 Meiji Seika Kaisha, Ltd. Tetrahydrobenzindole derivatives
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US20060235012A1 (en) * 2003-06-16 2006-10-19 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
EP1637521B1 (en) * 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Novel tricyclic heterocycle compound
EP1714961B1 (en) * 2004-02-12 2015-12-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
WO2006011750A1 (en) * 2004-07-27 2006-02-02 C & C Research Laboratories Tetrahydro-beta-carbolinone derivatives and process for preparing the same
EP1851219A1 (en) * 2005-02-14 2007-11-07 Miikana Therapeutics, Inc. Fused heterocyclic compounds useful as inhibitors of histone deacetylase
JP5287257B2 (ja) * 2007-02-07 2013-09-11 アステラス製薬株式会社 アシルグアニジン誘導体
DE102007009264A1 (de) * 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen
CA2683453C (en) * 2007-04-05 2013-06-11 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-.beta.]indoles, methods for the production and use thereof
RU2007139634A (ru) * 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
JP5366211B2 (ja) * 2007-12-18 2013-12-11 国立大学法人富山大学 アルドース還元酵素阻害活性を有する縮合三環化合物
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CA2719412A1 (en) * 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy

Similar Documents

Publication Publication Date Title
JP2013505946A5 (US07981874-20110719-C00313.png)
JP2013505945A5 (US07981874-20110719-C00313.png)
JP2011515483A5 (US07981874-20110719-C00313.png)
JP2011515482A5 (US07981874-20110719-C00313.png)
JP2013505947A5 (US07981874-20110719-C00313.png)
JP2008200039A5 (US07981874-20110719-C00313.png)
JP2018517746A5 (US07981874-20110719-C00313.png)
JP2014051526A5 (US07981874-20110719-C00313.png)
CR20220312A (es) Compuestos tricíclicos sustituidos
JP2012528865A5 (US07981874-20110719-C00313.png)
JP2011500725A5 (US07981874-20110719-C00313.png)
JP2016505586A5 (US07981874-20110719-C00313.png)
JP2020506951A5 (US07981874-20110719-C00313.png)
JP2012532137A5 (US07981874-20110719-C00313.png)
JP2018511628A5 (US07981874-20110719-C00313.png)
JP2004534846A5 (US07981874-20110719-C00313.png)
JP2014521688A5 (US07981874-20110719-C00313.png)
JP2018504437A5 (US07981874-20110719-C00313.png)
JP2020504112A5 (US07981874-20110719-C00313.png)
JP2013544846A5 (US07981874-20110719-C00313.png)
WO2010000372A3 (en) New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
RU2396264C2 (ru) Производные хромана и их применение в качестве лигандов 5-нт рецептора
JP2017511321A5 (US07981874-20110719-C00313.png)
JP2018538248A5 (US07981874-20110719-C00313.png)
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b